Pfizer and GSK spearhead development of promising RSV vaccines

Vaccines for RSV from GSK and Pfizer to be analysed by a panel of experts with a view to informing a decision from the US FDA on their approval.
The next stage in an exciting head-to-head between Pfizer and GSK to develop the first vaccine for respiratory syncytial virus (RSV) will take place this week as a panel of experts for the US FDA come to assess the vaccines.
RSV is common cold-like respiratory virus that is responsible for the deaths of around 14,000 older adults in the US every year. A vaccine that could protect the most vulnerable from this virus would be a big step forward.
For GSK and Pfizer it would also mean securing their place in the market, with a return of up to $10 billion according to recent estimates.
The vaccine, for which approval is sought for use in adults aged 60 and over, will come under scrutiny from a panel of experts, who will then provide an independent report for the FDA to consider, eventually deciding on final approval by May of this year. If all goes to plan then the vaccine would be available for patients in time for the seasonal increase in virus prevalence in winter, providing timely protection.
Research into RSV has been ongoing since the 1960s, so to finally have a breakthrough in the development of a vaccine is a real win for the industry and a credit to the recent advances in the fields of vaccine development and infectious diseases.
"RSV is the last of the great big respiratory viruses that afflict our population on an annual basis," stated William Schaffner of Vanderbilt University Medical Centre.
Other leaders in the field, Merck, Moderna and Johnson & Johnson have also developed RSV vaccines, which are currently undergoing clinical trials.
GSK and Pfizer have been leading the charge after initial results from late-stage studies conducted by the two companies demonstrated that their vaccines prevented the occurrence of respiratory disease after infection by RSV.
The key results were as follows: GSK's vaccine was 82.6% effective in preventing lower respiratory tract disease in people of over 60 years old, and 94.1% effective in preventing severe disease in this population.
The vaccine from Pfizer was 66.7% effective in preventing lower respiratory tract disease that occurs with over two symptoms, and 85.7% effective against illness with over three symptoms.
The results are extremely promising and a favourable outcome from the panel assessment is expected with a view to approving the vaccines in the future.


Related News
-
News Samsung Biologics invests in new plant to expand Bio Campus
Samsung Biologics, the leading end-to-end CDMO, is set to start building a new plant based in North Korea, to expand its biomanufacturing capabilties. -
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. -
News Pfizer acquires Seagen to become the leading innovator in cancer therapy
Pfizer makes a bold move in the acquisition of innovative cancer therapy biotechnology company Seagen, the move means the doubling of their pipeline of early-stage therapeutics and gaining four leading ADC therapies. -
News Pfizer's zavzpret nasal spray gains approval for treatment of migraine
Pfizer makes a breakthrough in migraine treatment with the approval from the US FDA of its new drug Zavzpret™ (zavegepant) in the form of a nasal spray, which adds to their current portfolio of oral migraine prevention and treatment therapies.&nb... -
News Fully biodegradable nutraceutical packaging an industry first
An agreement signed between TricorBraun and BioBottles will give nutraceutical companies (and potentially pharmaceutical companies) in the US and Canada access to the industry’s first fully biodegradable packaging option. -
News Can we make clinical trials more diverse?
The US FDA are hoping to lead the way in addressing the lack of diversity and representation in clinical trials when developing medicines through new legislation. -
News Using AI to determine drug compounds to curb the opioid crisis
Researchers have developed a computer model, that learns using AI, to identify potential drug compounds that can be used to block opioid receptors in the brain. -
News 100 years of pharmaceutical packaging excellence - Pharmapack 2023 Premium Partner interview
West Pharmaceutical Services, Inc. speaks to CPHI Online about celebrating their 100-year anniversary as an industry leader, and how they plan to continue driving innovation after the challenges posed from global disruptions in the last few years.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance